NOVOLOG *
Manufacturer Details
NOVO NORDISK
Compositions:
Insulin Aspart rDNA origin 100 units/ml injection slution,
|
Strength
|
Rate
|
Packing Style
|
|
100units/ml inj
|
0.00
|
in 10ml vials and 3ml Penfill cartridges /FlexPen prefilled syringes
|
List of Related Indications:
List Of Drugs:
- Insulin Aspart - rDNA Origin - Antidiabetic Agents
Indication Type Description:
Indication:
Diabetes mellitus
Patent Expiry Date of drugs (Ref - IDMA Publication)
Chemical Category Manufacturer/ US Patent
Ingredient- Marketer Expiration Date
Insulin Aspart Diabetes Nov Nordisk 28-08-2013
Contra-Indications:
Special Precautions/Warnings-
Renal function impairment -
The dose requirements for insulin may be reduced in patients with renal impairment
Hepatic function impairment-
The dose requirements for insulin may be reduced in patients with hepatic impairment
Dosages/ Overdosage Etc:
Indication-
Diabetes mellitus
Dosage-
0.5 and 1unit/kg /day. when used with a meal related subcutaneous injection regimen,
50% to 70% of total insulin requirements may be provided by Novolog and the
reminder by an intermediate or long acting insulin.
Because of Novologs comparitively rapid onset and short duration of glucose-lowering
activity, some patients may require more basal insulin and more total insulin to prevent
premeal hyperglycemia when using Novolog than using human regular insulin
